Multiple plexiform fibromas, Schwannomas and accoustic neuromas are a hallmark neurofibromatosis, which condition also presents with other findings and symptoms. It can appear as cafe-au-lait spots and bumps under the skin, or it can lead to complications that include blindness, scoliosis and disfigurement. Fibromas can cause pain and compromise other organs. Few treatments are available, although many novel agents are being studied.
Among these is Avastin. Information is limited and restricted to case reports. VEGF blockade with bevacizumab improved hearing in some, but not all, patients with neurofibromatosis type 2 and was associated with a reduction in the volume of most growing vestibular schwannomas(Plotkin). Mautner reproted 2 cases of schwannoma regression onA vastin. Clearly this is very preliminary. There is an onging study: Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2), NCT01207687.
A. C. Williams, J. Lucas, M. A. Babcock, D. H. Gutmann, B. Rorf, and B. L. Maria Neurofibromatosis Type 1 Revisited Pediatrics, January 1, 2009; 123(1): 124 - 133.
Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009 Jul 23;361(4):358-67.
Victor-Felix Mautner, Rosa Nguyen et al Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2 Neuro Oncol (2010) 12 (1): 14-18.